Bayer to Present Data that Reinforce Established Prostate Cancer Portfolio at 2021 ASCO GU Cancers Symposium
Retrieved on:
Monday, February 8, 2021
Health, Science, Research, Clinical trials, Oncology, Anatomy, Chemistry, Organ systems, Nitriles, Nonsteroidal antiandrogens, Chloroarenes, Pyrazoles, Antiprogestogens, Darolutamide, Prostate cancer, Radium-223, Prostate, NUBEQA® (darolutamide)2, Xofigo® (radium Ra 223 dichloride) Injection3, Prostate Cancer, Oncology at Bayer, Bayer
Bayer announced today that new NUBEQA (darolutamide) and Xofigo (radium Ra 223 dichloride) data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium , taking place from February 11-13, 2021.
Key Points:
- Bayer announced today that new NUBEQA (darolutamide) and Xofigo (radium Ra 223 dichloride) data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium , taking place from February 11-13, 2021.
- Our priority at Bayer is to advance the treatment of men with prostate cancer across the disease continuum.
- The focus of our data at ASCO GU 2021 is reflective of our patient-centric approach to prostate cancer research, said Scott Z.
- NUBEQA (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.